A SNP in ABCG2 (rs2231137) that reportedly contributes to differential survival outcomes and toxicities in AML patients showed no significant effect on the MTX plasma concentration and was used as a negative control here (Fig. 2). Here, ABCG2 is linked to acute myeloid leukemia.